Medipharm Labs Corp (LABS) — Cash Flow-to-Debt Ratio
Medipharm Labs Corp (LABS) has a Cash Flow-to-Debt Ratio of -0.09x as of March 2026, meaning its operating cash flow of CA$-778.00K could theoretically repay 0% of its total liabilities (CA$8.52 Million) in one year. Explore LABS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medipharm Labs Corp Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Medipharm Labs Corp across 10 annual periods. Also explore Medipharm Labs Corp (LABS) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Medipharm Labs Corp (2016–2025)
Year-by-year debt coverage analysis for Medipharm Labs Corp. For market capitalisation and broader financial context, see Medipharm Labs Corp market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.55x | CA$-5.50 Million | CA$9.93 Million | ▼ -20.3% |
| 2024 | -0.46x | CA$-4.86 Million | CA$10.55 Million | ▲ +59.2% |
| 2023 | -1.13x | CA$-12.34 Million | CA$10.93 Million | ▲ +33.3% |
| 2022 | -1.69x | CA$-16.07 Million | CA$9.49 Million | ▼ -18.1% |
| 2021 | -1.43x | CA$-13.21 Million | CA$9.21 Million | ▼ -51.1% |
| 2020 | -0.95x | CA$-37.77 Million | CA$39.82 Million | ▼ -41.2% |
| 2019 | -0.67x | CA$-25.27 Million | CA$37.60 Million | ▲ +10.0% |
| 2018 | -0.75x | CA$-11.11 Million | CA$14.89 Million | ▼ -1235.1% |
| 2017 | 0.07x | CA$166.00K | CA$2.52 Million | ▲ +105.6% |
| 2016 | -1.17x | CA$-54.69K | CA$46.73K | — |